Edition:
United States

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

13.85USD
26 May 2017
Change (% chg)

$-0.10 (-0.72%)
Prev Close
$13.95
Open
$14.00
Day's High
$14.10
Day's Low
$13.85
Volume
49,574
Avg. Vol
110,006
52-wk High
$20.68
52-wk Low
$10.77

Latest Key Developments (Source: Significant Developments)

Meridian Bioscience comments on FDA matter involving its subsidiary
Wednesday, 17 May 2017 03:30pm EDT 

May 17 (Reuters) - Meridian Bioscience Inc :Meridian Bioscience comments on FDA matter involving its subsidiary, Magellan Diagnostics.Unit currently working with U.S. Food and Drug Administration (FDA) regarding use of venous blood with its leadcare testing systems.Meridian Bioscience Inc says unit's capillary samples are not affected by notification.FDA issued a warning that results from venous samples may be underestimated and provide inaccurate results.Unit currently undertaking efforts to move customers to capillary blood testing with Leadcare II testing system as a corrective action.Meridian and Magellan do not expect this occurrence to cause any material adverse effect to meridian's financial results.Meridian & Magellan will continue to work closely with FDA and CDC to address concerns identified with venous samples.  Full Article

Meridian Bioscience says CEO John Kraeutler to retire
Wednesday, 10 May 2017 09:00am EDT 

May 10 (Reuters) - Meridian Bioscience Inc :Meridian Bioscience engages Korn Ferry to conduct CEO search as John Kraeutler announces plans to retire.Meridian Bioscience Inc - Kraeutler plans to continue to serve in capacity of CEO until his successor is found.Meridian Bioscience - Kraeutler will be available to assist new CEO during transition and onboarding phases, will remain executive chairman of board.  Full Article

Meridian Bioscience sees FY 2017 revenue $193 mln to $199 mln
Thursday, 27 Apr 2017 07:45am EDT 

April 27 (Reuters) - Meridian Bioscience Inc :Meridian bioscience reports second quarter 2017 operating results, declares regular cash dividend, and reaffirms fiscal 2017 guidance.Sees fy 2017 earnings per share $0.64 to $0.69.Q2 earnings per share $0.22.Sees fy 2017 revenue $193 million to $199 million.Fy2017 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Q2 net revenues $54.1 million, up 6%.Q2 earnings per share view $0.19, revenue view $51.2 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $194.6 million -- Thomson Reuters I/B/E/S.Meridian bioscience inc - revenue and earnings guidance does not include impact of any acquisitions company may complete during fiscal 2017.  Full Article

Meridian Bioscience Inc signs an exclusive distribution agreement with Biofirm Technologies
Tuesday, 7 Mar 2017 09:17am EST 

Meridian Bioscience Inc :Meridian Bioscience Inc- Magellan Diagnostics , a business unit signed an exclusive distribution agreement with Biofirm Technologies.  Full Article

Meridian Bioscience Q1 earnings per share $0.15
Wednesday, 25 Jan 2017 07:30am EST 

Meridian Bioscience Inc : Meridian Bioscience reports first quarter 2017 operating results, reduces regular cash dividend, and revises fiscal 2017 guidance downward . Q1 earnings per share $0.15 . Q1 revenue $46.8 million versus I/B/E/S view $51.1 million . Q1 earnings per share view $0.20 -- Thomson Reuters I/B/E/S . Sees FY 2017 earnings per share $0.64 to $0.69 . Sees FY 2017 revenue $193 million to $199 million . Meridian Bioscience Inc - revised fiscal 2017 annual indicated cash dividend rate to $0.50 per share . Fy2017 earnings per share view $0.82, revenue view $206.1 million -- Thomson Reuters I/B/E/S .Meridian Bioscience Inc - "taking further action to align resources, reduce expenses and optimize investments in product development".  Full Article

Meridian Bioscience says Magellan Diagnostics signed exclusive distribution agreement with Medcaptain Medical Technology
Tuesday, 20 Dec 2016 02:00pm EST 

Meridian Bioscience Inc - : Meridian Bioscience Inc- Magellan Diagnostics business unit has signed an exclusive distribution agreement with Medcaptain Medical Technology Co., Ltd .Meridian Bioscience Inc - Distribution activities with Medcaptain will begin in January 2017.  Full Article

Meridian Bioscience reports Q3 EPS of $0.21
Thursday, 28 Jul 2016 08:00am EDT 

Meridian Bioscience Inc : Meridian Bioscience reports third quarter 2016 operating results, declares regular cash dividend, and updates fiscal 2016 guidance . FY 2016 earnings per share view $0.88, revenue view $203.4 million -- Thomson Reuters I/B/E/S . Sees FY 2016 NON-GAAP earnings per share $0.86 to $0.90 . Q3 earnings per share $0.21 . Sees FY 2016 revenue $195 million to $200 million . Q3 earnings per share view $0.22 -- Thomson Reuters I/B/E/S .Q3 revenue $50.7 million versus I/B/E/S view $52.8 million.  Full Article

Meridian Bioscience Inc acquires Magellan Diagnostics Inc
Thursday, 24 Mar 2016 04:15pm EDT 

Meridian Bioscience Inc:Has completed the acquisition of Magellan Biosciences Inc and its wholly owned subsidiary Magellan Diagnostics Inc.Expects Magellan to be accretive to earnings per share during the second half of calendar 2017.Says Meridian will finance purchase price of $66 million using a combination of cash on hand and a $60 million five-year term loan.  Full Article

Meridian Bioscience Inc reaffirms FY 2016 guidance
Wednesday, 27 Jan 2016 07:30am EST 

Meridian Bioscience Inc:Reaffirms FY 2016 2016 guidance of per share diluted earnings between $0.86 and $0.90 on net revenues of $195 million to $200 million.  Full Article

Meridian Bioscience announces investment in Oasis Diagnostics
Thursday, 12 Nov 2015 03:00pm EST 

Meridian Bioscience Inc:Announced that it has made a minority investment in Oasis Diagnostics Corporation, with the right to acquire Oasis in the future.Says terms of the transaction were not disclosed.  Full Article

More From Around the Web

BRIEF-Meridian Bioscience comments on FDA matter involving its subsidiary

* Meridian Bioscience comments on FDA matter involving its subsidiary, Magellan Diagnostics